This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Plan Cancer | |
|---|---|
| Name | Plan Cancer |
| Specialty | Oncology |
Plan Cancer
Plan Cancer is a medical condition described in contemporary oncologic literature as a multifocal neoplasm affecting architecturally distinct tissues. First characterized in case series from major centers, it has drawn interest from clinicians at Mayo Clinic, Memorial Sloan Kettering Cancer Center, and researchers at National Cancer Institute. Contemporary reviews have appeared in journals associated with American Society of Clinical Oncology and research consortia including European Society for Medical Oncology and Cancer Research UK.
Plan Cancer typically presents as a heterogeneous tumor type involving mixed histologies arising within a defined anatomical region. Early descriptions referenced cohorts treated at Johns Hopkins Hospital and Massachusetts General Hospital, where multidisciplinary teams including pathologists from College of American Pathologists and radiologists from Radiological Society of North America contributed to defining diagnostic criteria. Clinical management often requires integration of standards from World Health Organization diagnostic frameworks and staging conventions adapted from Union for International Cancer Control.
Epidemiologic patterns have been reported by surveillance programs such as Surveillance, Epidemiology, and End Results Program and registries run by European Cancer Information System. Demographic analyses reference populations served by institutions like Cedars-Sinai Medical Center and public health agencies including Centers for Disease Control and Prevention and Public Health England for incidence trends. Risk factors under investigation include exposures documented in occupational cohorts at National Institute for Occupational Safety and Health, familial predisposition observed in pedigrees evaluated at Broad Institute and germline variants studied through consortia such as The Cancer Genome Atlas. Case-control studies have compared cohorts from Harvard T.H. Chan School of Public Health and University of Oxford.
Molecular characterization draws on sequencing efforts by The Cancer Genome Atlas, International Cancer Genome Consortium, and laboratories at Cold Spring Harbor Laboratory. Altered signaling pathways implicated include those described in seminal work from Dana-Farber Cancer Institute and mechanistic studies referencing proteins cataloged by UniProt. Tumor microenvironment studies cite techniques developed at Max Planck Institute and immune profiling approaches pioneered at Scripps Research Institute. Key biological phenomena are contextualized alongside pathways first detailed in research from Rockefeller University and functional experiments reported from Stanford University School of Medicine.
Diagnostic algorithms incorporate imaging modalities standardized by American College of Radiology and histopathologic criteria influenced by classifications from World Health Organization. Imaging workups often utilize protocols established by European Society of Radiology and nuclear medicine guidance from Society of Nuclear Medicine and Molecular Imaging. Pathology reporting conventions align with guidelines from College of American Pathologists and staging adaptations reference Union for International Cancer Control and American Joint Committee on Cancer. Molecular diagnostics employ assays validated by laboratories at Mayo Clinic and commercial partners with regulatory oversight from U.S. Food and Drug Administration.
Therapeutic strategies are multidisciplinary, incorporating surgical techniques refined at centers such as Cleveland Clinic and systemic therapies developed through trials conducted by groups like Eastern Cooperative Oncology Group and National Comprehensive Cancer Network. Radiation protocols reference advances reported by European Organisation for Research and Treatment of Cancer and devices manufactured by companies collaborating with International Atomic Energy Agency dosimetry programs. Targeted agents and immunotherapies derive from drug development programs at Novartis, Roche, and biotechnology firms spun out of MIT and University of California, San Francisco, often prescribed following guidelines from American Society of Clinical Oncology.
Prevention strategies are informed by public health campaigns led by World Health Organization and screening frameworks adapted from programs at U.S. Preventive Services Task Force and National Health Service (England). Population-level risk reduction references interventions promoted by American Cancer Society and lifestyle cohorts maintained by Framingham Heart Study investigators for modifiable exposures. Screening research parallels methods used in established programs for breast cancer screening, colorectal cancer screening, and protocols piloted by academic networks at University College London.
Ongoing research is coordinated through cooperative groups including National Cancer Institute-sponsored networks, European Organisation for Research and Treatment of Cancer, and translational consortia at Cold Spring Harbor Laboratory and Broad Institute. Clinical trials are registered with platforms affiliated with ClinicalTrials.gov and conducted at trial sites such as MD Anderson Cancer Center and Vanderbilt-Ingram Cancer Center. Emerging areas include precision oncology approaches influenced by work at Memorial Sloan Kettering Cancer Center and biomarker discovery pipelines developed at Wellcome Trust Sanger Institute. Collaborative efforts often involve biotechnology partners and funding agencies such as National Institutes of Health and philanthropic organizations like Wellcome Trust.